On December 28, 2015, the Ministry of Health of Ukraine held a working meeting where national medicinal products policy was discussed. Following the meeting the subject matter experts, involved into nine different areas, were divided into sub-working groups.
Dmytro Aleshko, Legal Alliances' Partner, became a member of the working group on essential medicines selection within the implementation of the project for National Medicinal Products Policy development. Mr. Aleshko shall fulfill the assigned mission together with Tatyana Dumenko, Head of Department of Rational Pharmacotherapy at State Expert Center of MoH of Ukraine, Oksana Lebega, USAID/SIAPS Senior Technical Advisor - Pharmacovigilance and Rational Drug Use, and Taras Lyaskovsky, acting Head of Pharmaceutical Activity and Pharmaceuticals Quality Directorate of MoH of Ukraine.
The sub-working group members are responsible for the implementation of essential medicines concept, establishment of the state priorities for participation in the pharmaceutical sector according to national morbidity rate. The sub-working group tasks also include the development of essential medicines selection criteria (reliable and sufficient evidence, economic efficiency, etc.) and establishment of the actual selection process (assignment of permanent commission, etc.).
The event focused on the transformation of Ukraine's intellectual property sector on its path toward European integration.
Improving access to safe and affordable medicines for the Ukrainian population is one of the Government of Ukraine's top priorities. SAFEMed Activity (2017-2025) has supported this effort by appIying health system strengthening best practices.
The Ministry of Health website has posted a notice about the release of a revised draft order of the Ministry of Health ‘On Approval of Amendments to Certain Re
On 25 September, a webinar was held on the topic: ‘180 days of new drug price regulation. Results, prospects and practical advice.’ The event was organized by LA Law Firm in partnership with Proxima Research International.
